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Gene transfer into skeletal mu&e via simple plasmid injection in vivo has many potential uses but these are severely constrained by the low efficiency 
of this technique. Muscle regeneration, induced by the myotoxic local anaesthetic bupivacaine, siguiticantly increased gene expression following 
plasmid injection 3-7 days after bupivacaine treatment. Much of this effect can be attributed to uptake and expression of the plasmid by a greater 
number of muscle fibres, up to 9% of the mouse tibialis anterior muscle. A similar significant increase in expression was observed in the naturally 
regenerating muscle of the dystrophic mci!x mouse when compared to the control C57BUlO strain, 
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Striated muscle has the almost unique ability to take 
up and express naked plasmid DNA. This property of 
skeletal muscle was first demonstrated by Wolff et al. 
in 1990, when they reported the expression of marker 
genes (cbloramphenicol acetyltransferase [CAT and /3- 
galactosidase v-gal]) following the direct injection of 
plasmid DNA solutions into rodent muscles [l]. Since 
then a number of investigators have documented this 
phenomenon in both skeletal f2,3] and cardiac [4-n 
muscle of rodents, skeletal [g] and cardiac muscle [?&lo] 
of other mammals, and the skeletal muscle of fish [ 1 l]. 
Other tissues do not appear to intem~ise and express 
si~~~nt amounts of naked plasmid DNA in vivo, 
with the possible exception of neural tissues 1121. 
The direct transfer technique has been proposed as a 
simple and cheap means of effecting somatic gene ther- 
apy, with little danger of genetic damage as the DNA 
appears to persist as an extrachromosomal circular 
plasmid [1,13]. Additionally, no immune reactions or 
adverse side effects were noted in a recent study in 
nonhuman primates, even after repeated treatments [g]. 
A further advantage is the injected plasmids continue to 
show expression for at least 19 months in mice [13]. 
Recently, direct DNA injection has been used suc- 
cessfully as a means of vaccinating mice against influ- 
enza 1141. Other uses of this gene transfer technique 
include: examination of skeletal and cardiac specific 
control elements of striated muscle genes [151, examina- 
tion of the distribution of recombinant gene products in 
vivo [2], and testing constructs intended for expression 
*Corresponding author. Fax: (44) (71) 388-2342. 
in the muscles of transgenic mice (Wells et al,, unpub- 
lished obse~ations). 
All of the above uses are hampered by the substantial 
variation in expression following a given injection 
(S.E.M. of 25--60% of the mean [3]) and the transfection 
of only a limited number of myofibres [2]. A number of 
variables affecting the technique have been identified, 
including different plasmid preparations, the solute 
used, innervation and muscle damage [3]. We recently 
reported two additional variables, namely the age and 
sex of the treated animal [16J Variation in expression 
between injections appears to be reduced if the muscle 
is pie-treated with a sucrose solution fl-;lf. In this report 
increased transfection and expression are associated 
with muscle regeneration, both natural and induced. 
2. MATERIALS AND METHODS 
2.1. Plasmid production 
The experiments utilised the SV40 early promoter coupled to the 
chlorampbenicol acetyhransferase reporter 8ene @CATControl. 
Promega) and the RSV promoter coupled to the &fl-galactosidase re-
porter gene [IQ. Plasmid DNA was prepared by standard caasimn 
chloride centrifugation [19] and was checked for the purity of the 
supercoiled DNA by gzl electrophoresis. 
DNA 
C57BVlO S&n mice, and the derived dystrophic mdu line 1201, were 
reared in a barrier maintained colony with food and water available 
ad hbitum. The myotoxic agent bupivacaine (0.5% Marcain, Astra 
Pharmaceuticals) was injected into the left tibialis anterior muscle at 
2.5 ,&/g body weight of mice auaesthetized with a mixture of Hypnorm 
and Hypnovel [21]. Three to twenty-one days later 50-100 pg of 
supercoiled plasmid DNA in PBS, fmal volume 50 fl, was injected 
through a 28-gau8e needle (insulin syringe) into the middle of both left 
aud right tibialis anterior muscles of the mice, again under 8eneral 
anaesthesia 
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2.3. Chloranaphenicol acetyl transferase assays 
Five days after plasmid injection the mice were sacrificed by cervical 
dislocation and the tibialis anterior muscle excised. The muscle was 
frozen in liquid nitrogen and ground to a fine powder using a pre- 
cooled mortar and pestle. The sample was then transferred to a 1.5 ml 
tube and resuspended in 200 ~1 of 0.25 M Tris-HCl, pH 7.8. The 
sample was subjected to three cycles of freezing and thawing (37’C), 
centrifuged using a Hereus microfuge at 13,000 rpm for 5 min, and the 
supernatant incubated at 65°C to inactivate ndogenous acetyltrans- 
ferases. After centrifugation at 13,000 rpm for 2 min, the supematant 
was mixed with 100 ~1 of 1 M Tris-HCl, pH 7.8, 20 ~1 of acetyl 
coenxyme A (4 mg/ml) and 2 ~1 “C-labelled chloramphenicol (57.9 
mCi/mmol, 0.05 mCi/ml). The mixture was incubated at 37°C for 2 
h and the product was resolved by thin-layer chromatography [19]. 
X-Ray film was exposed overnight to the TLC plates. CAT activity 
was measured as the percentage of chloramphenicol conversion to 
acetylated forms using a laser densitometer (Chromoscan 3, Joyce- 
Loebl). 
2.4. jSgalactosi&e histochemistry 
Nine days after plasmid injection the mice were sacrificed by cervi- 
cal dislocation. After dissection the tibialis anterior muscles were fixed 
for 30 min in 0.5% glutaraldehyde in phosphate buffer (100 mM, pH 
7.0, 1 mM MgCl,, 0.02% Nonidet-P40). After fixation muscles were 
sliced transversely in approximately l-2 mm sections, Sxed for a 
further 15 min, and then rinsed in 3 changes of phosphate buffer. 
Muscle slices were stained to reveal /3-galactosidase activity with X-gal 
solution (10 mM PO, buffer, 1 mM MgCl,, 0.15 M NaCl, 33 mM 
J&Fe&N),, 33 mM &Fe(CN),, 0.1% X-galactosidase in dimethylfor- 
mamide). After incubation at 37’C for 45 min the number of p-gal 
positive fibres could be counted using a dissecting microscope. Counts 
were confirmed by dehydrating, wax embedding, and sectioning the 
muscle slices. 
3. RESULTS 
3.1. Bupivacaine pre-treatment enhances expression 
Fourteen-week-old male C57BYlO mice were injected 
with bupivacaine in the left tibialis anterior muscle. 
Three, seven or twenty-one days later 100 pg of SV40- 
CAT plasmid in 50 ,ul of PBS was injected into the left 
and the right tibialis anterior muscles. Five days later 
l 
3 days 7 days 21 days 
Days after bupivacaine treatment 
Fig. 1. Mice, with the left tibialis anterior muscle treated with bupiva- 
caine 3, 7 or 21 days earlier, were injected with 100 pug of SV40-CAT 
plasmid. Significant differences in CAT activity were seen between the 
pre-treated (black bars) and the untreated (striped bars) muscles at 3 
and 7 days (*P C 0.02, ***P < 0.001) but not at 21 days. 
the mice were sacrificed and the muscle extract was 
assayed for CAT activity (Fig. 1). Mice injected three 
days after bupivacaine treatment showed significantly 
increased CAT activity in the pre-treated muscle com- 
pared to the contralateral control (n = 7, P < 0.02). 
Mice treated with bupivacaine seven days prior to the 
injection of plasmid showed similar dramatic increases 
in expression on the treated side compared to the con- 
tralateral control (n = 5, P < 0.001) but this effect was 
lost in muscles treated twenty-one days before plasmid 
injection (n = 5, N.S.). Comparisons analyzed with cor- 
related t-tests [22]. 
3.2. Bupivacaine pre-treatment enhances transfection 
Eleven-week-old male C57Bl/lO mice were injected 
with bupivacaine in the left tibialis anterior muscle. Five 
days later 100 ,ug of RSV-/?gal plasmid in 50 ~1 PBS was 
injected into the left and the right tibialis anterior mus- 
cles. Nine days later the mice were sacrificed and the 
muscles stained for fibres expressing /?-galactosidase 
(Fig. 2). Muscles pre-treated with bupivacaine had 3 
times the number of /?-galactosidase positive fibres as 
the contralateral controls (n = 4, P < 0.05, correlated 
t-test). In one animal 9% of the muscle fibres were trans- 
fected by this single treatment. 
3.3. Natural regeneration enhances expression 
Eight-week-old male C57BYlO and mdx mice were 
injected with bupivacaine in the left tibialis anterior 
muscle. Five days later 50 ,ug of SV40-CAT plasmid in 
50 ~1 PBS was injected into the left and the right tibialis 
anterior muscles. Five days later the mice were sacri- 
ficed and the muscle extract was assayed for CAT activ- 
ity (Fig. 3). As before, pre-treatment with bupivacaine 
enhanced gene expression in the C57BYlO mice. This 
bupivacaine effect was not seen in the mdx strain but 
these mice show significantly higher gene expression 
without pre-treatment compared to the C57BUlO mice 
(n = 9, P < 0.05, t-test). 
4. DISCUSSION 
Bupivacaine, a local anaesthetic, is myotoxic when 
injected into skeletal muscle [23]. It causes increased 
membrane permeability to calcium ions which leads to 
fibre hypercontraction and necrosis [24]. Innervation, 
blood supply, satellite cells and connective tissues are 
not significantly disturbed by this treatment [25]. The 
necrotic muscle regenerates very rapidly; myotubes are 
apparent by three days after treatment, much of the 
fibre architecture is re-established by seven days and the 
muscle phenotype is fully restored by 21 days [26,27]. 
Hence, it is not surprising that enhanced plasmid ex- 
pression, observed during regeneration, was not seen 
when plasmids were injected into muscles 21 days after 
bupivacaine treatment. 
The improved efficiency of plasmid gene transfer into 
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Fig. 2. Mice, with the left tibialis anterior muscle treated with bupiva- 
caine 5 days earlier, were injected with 100 pg of RSV-pgal plasmid. 
A significant difference in the number of &gal positive fibres was 
observed when comparing the pre-treated (black bar) and the un- 
treated (striped bar) muscles (P c 0.05). 
regenerating muscle may be due to one or more of a 
number possible factors. Muscle destruction, inflamma- 
tion and the fo~ation of small myotubes may allow for 
an improved dist~bution of the injected plasmid and 
increased access of the DNA to the sarcolemma of the 
muscle. Variation in the efficiency of gene transfer be- 
tween individual injections has been attributed to differ- 
ences in plasmid distribution within the muscle [17]. 
Alternatively, the process of regeneration may be asso- 
ciated with a higher density of the putative receptors 
involved in the uptake of the DNA. DNA uptake by 
skeletal muscle has been postulated to be an active up- 
take process involving caveolae [28]. Translocation to 
the nucleus may also be affected by regeneration, per- 
haps associated with altered Iysosomal dynamics. Fi- 
nally, muscle fibre growth may lead to increased tran- 
scription of the plasmid DNA, as suggested by Wells 
and Goldspink [16]. 
” 
mdx C57BlllO 
Fig. 3. C57BYlO and mdx mice, with the left tibialis anterior muscle 
treated with bupivacaine 5 days earlier, were injected with 50 pug of 
SV40-CAT plasmid. A sign&ant difference in CAT activity was seen 
between the untreated muscles of the C57BYlO and mdx mice (striped 
bars, P < 0.05). CAT expression increased with bupivacaine pre-treat- 
ment in the C57B1110 mice but bupiv~edid not increase xpression 
in the &X mice (black bars). 
Regardless of the mode of action, regeneration is 
none the less a very useful means of increasing the effi- 
ciency of gene transfer with this plasmid injection 
method. Possible applications for natural or induced 
regeneration as an adjunct to gene transfer include: gene 
therapy, DNA based vaccination protocols, and for ex- 
amination of muscle gene function in vivo. The latter 
will become more important as differences are increas- 
ingly recognised between gene activity in vitro, gener- 
ally in tr~sfo~ed permanent cell lines, and perform- 
ance in vivo [29,30]. As such, this simple technique may 
in part substitute for the expensive and time-consuming 
production of transgenic mice for the in vivo analysis 
of gene function. 
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